• Product NameQuisinostat (JNJ-26481585)
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityQuisinostat (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.
• Target NameHDAC inhibitor
• CAS No. 875320-29-9
• Calculated MW 394.476
• Formulation C21H26N6O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO
  Pathways:Chromatin/Epigenetic; DNA Damage/DNA Repair; NF-κb
  Receptor:HDAC1; HDAC10; HDAC11; HDAC2; HDAC3; HDAC4; HDAC5; HDAC8
  Boling pt:
  Melting pt:
  Solubility:DMSO:79 mg/mL (200.26 mM)Ethanol:<1 mg/mL (<1 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Arts J, et al. Clin Cancer Res, 2009, 15(22), 6841-6851.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting